NO20070174L - Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi - Google Patents

Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi

Info

Publication number
NO20070174L
NO20070174L NO20070174A NO20070174A NO20070174L NO 20070174 L NO20070174 L NO 20070174L NO 20070174 A NO20070174 A NO 20070174A NO 20070174 A NO20070174 A NO 20070174A NO 20070174 L NO20070174 L NO 20070174L
Authority
NO
Norway
Prior art keywords
insulin
preparations
control
prevention
methods
Prior art date
Application number
NO20070174A
Other languages
English (en)
Norwegian (no)
Inventor
Daniel T Green
Robert R Henry
Original Assignee
Diobex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diobex Inc filed Critical Diobex Inc
Publication of NO20070174L publication Critical patent/NO20070174L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20070174A 2004-06-29 2007-01-10 Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi NO20070174L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58444904P 2004-06-29 2004-06-29
PCT/US2005/022812 WO2006004696A2 (en) 2004-06-29 2005-06-27 Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Publications (1)

Publication Number Publication Date
NO20070174L true NO20070174L (no) 2007-03-13

Family

ID=35783298

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070174A NO20070174L (no) 2004-06-29 2007-01-10 Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi

Country Status (11)

Country Link
EP (1) EP1778266A4 (enExample)
JP (1) JP2008505087A (enExample)
KR (1) KR20070029276A (enExample)
CN (1) CN101001638A (enExample)
AU (1) AU2005260025A1 (enExample)
CA (1) CA2571030A1 (enExample)
IL (1) IL180361A0 (enExample)
MX (1) MXPA06014970A (enExample)
NO (1) NO20070174L (enExample)
WO (1) WO2006004696A2 (enExample)
ZA (1) ZA200700708B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059764A1 (en) 2010-11-03 2012-05-10 Arecor Limited Novel composition comprising glucagon
EP3344231B1 (en) * 2015-09-04 2022-04-13 Latitude Pharmaceuticals, Inc. Stabilized glucagon solutions
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
US11357829B2 (en) 2017-02-03 2022-06-14 Vanderbilt University Systems, compositions and methods for treating diabetes
BR112020000447A2 (pt) * 2017-07-14 2020-07-21 Xeris Pharmaceuticals, Inc. métodos de tratamento de hiperinsulinismo congênito
WO2019108640A1 (en) * 2017-11-28 2019-06-06 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods and kits for evaluating metabolism
EP4171509A1 (en) * 2020-06-26 2023-05-03 Xeris Pharmaceuticals, Inc. Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
GB202109087D0 (en) * 2021-06-24 2021-08-11 Norwegian Univ Sci & Tech Ntnu Therapeutic methods and devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897551A (en) * 1971-04-05 1975-07-29 Lilly Co Eli Iodoglucagons and process for prolonging the biological activity of glucagon
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
JP2006508975A (ja) * 2002-11-18 2006-03-16 ファイザー・プロダクツ・インク ジペプチジルペプチダーゼｉｖを阻害するフッ素化環状アミド
NZ541365A (en) * 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Also Published As

Publication number Publication date
ZA200700708B (en) 2009-03-25
AU2005260025A1 (en) 2006-01-12
IL180361A0 (en) 2007-06-03
EP1778266A4 (en) 2009-09-09
WO2006004696A2 (en) 2006-01-12
CA2571030A1 (en) 2006-01-12
JP2008505087A (ja) 2008-02-21
EP1778266A2 (en) 2007-05-02
MXPA06014970A (es) 2007-03-07
CN101001638A (zh) 2007-07-18
WO2006004696A3 (en) 2006-10-26
KR20070029276A (ko) 2007-03-13

Similar Documents

Publication Publication Date Title
NO20053537L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.
NO340679B1 (no) Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
WO2020201041A3 (en) Glucose sensitive insulin derivatives
NO20054534L (no) Leveringssystem for legemiddel og celleterapi
Raz et al. Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)
MX2009007723A (es) Medicacion basada en exenatida y dalargina para el tratamiento de diabetes mellitus, su uso y modalidad de tratamiento.
TNSN08144A1 (en) Kit for parenteral administration of medicaments
NO20075199L (no) Treatment or prevention of pruritus
WO2006004696A3 (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
Danne Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus
Mest Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement
Kulasekararaj et al. Phase 3 study of danicopan, an oral complement factor D inhibitor, as add-on therapy to a C5 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with clinically evident extravascular hemolysis
EP3758689A4 (en) METHODS FOR THE PREVENTION AND TREATMENT OF HYPOGLYCEMIA IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES
Gadsby New treatments for type 2 diabetes—The DPP4 inhibitors
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
EA200800338A1 (ru) Профилактика и лечение офтальмологических осложнений диабета
NO20075508L (no) Stannsoporfinpreparater og administrering
MD20060037A (ro) Metodă de tratament al hepatitei virale acute C
Kim et al. Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion
Sanchez et al. Variceal bleeding and long-acting octreotide: a new addition to the armamentarium?
Xu et al. Acute efficacy of a novel anti-tissue factor pathway inhibitor antibody BAY 1093884 in hemophilia A mouse severe tail bleeding
Hussein Thalidomide, age, and future use in multiple myeloma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application